1 of 1
Story summary
- Bristol Myers Squibb reported a patient died after receiving its CAR-T therapy in a Phase 1 multiple sclerosis trial.
- After immunosuppression the patient contracted septic pneumonia and died, according to Bristol’s press release.
- Bristol paused the CAR-T studies in September after observing transient, reversible inflammatory events.
- Novartis disclosed three deaths in its CAR-T autoimmune trials, raising safety concerns.